Kalaris Therapeutics, Inc.

US$2.42As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:KLRSHealthcare
Country USA
PE (Fwd) •••
TSR 10Y CAGR —
Div yield —
ROE (79.91%)
Biotechnology
Beta (5Y) —
PE TTM —
TSR TTM (51.89%)
Mkt cap US$57.61M
ROIC (53.22%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$2.96
22.24%
230.79%
Hold 6|11|10|8|10
4Q25
1Q26
2Q26
3Q26
Earnings per share$
0.06
0.06
0.06
0.06
42.34%
25.36%
24.36%
13.59%
Revenue$M
4.105
4.068
4.121
4.027
7.75%
0.78%
(0.54%)
(2.79%)
Peers (US$57.61M)
Cap (US$)
PE
57.62M
—
56.15M
—
Capital
TTM
5Y
10Y
Leveragex
1.148
(0.633)
(0.466)
EBIT/Intx
0.503
0.085
0.101
Own earn%
162.20
21.98
26.47
Sh yield%
41.60
33.53
32.51
Owners
Insiders/Inst%
2.30
23.20
Short interest%
1.21
SBC / revenue%
1.90
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
12
Op margin range%
4–8
$1 testx
0.7
Incr. ROIC%
9